Abstract
Emerging data have shown the potential for circulating tumor DNA(ctDNA)-based MRD status to predict clinical recurrence in patients(pts) with stage I-III NSCLC. Moreover, research have shown that detection of ctDNA preceded radiographic progression by a median of 5.2 months. IMpower010 have shown a disease-free survival(DFS) benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II–IIIA NSCLC. Tislelizumab, an anti-PD-1 mAb, has shown improved efficacy in patients with advanced NSCLC with a tolerable safety profile.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
